BVT Call 125 NVO 21.03.2025/ DE000VD3N4K7 /
| 2024-08-09 7:52:20 PM | Chg.+0.400 | Bid9:58:19 PM | Ask9:58:19 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.940EUR | +25.97% | - Bid Size: - |
- Ask Size: - |
Novo Nordisk | 125.00 USD | 2025-03-21 | Call |
GlobeNewswire
06-28
SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteri...
GlobeNewswire
06-24
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American ...
GlobeNewswire
06-18
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesit...
GlobeNewswire
06-18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
06-17
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Share...
GlobeNewswire
06-13
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
06-11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06-10
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
05-31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
05-30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
05-15
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
